Similar case studies

REF impact found 17 Case Studies

Currently displayed text from case study:

Inhaled delivery of life-saving medicines - The Vectura story

Summary of the impact

Innovative formulation science to create and develop the commercially successful PowderHale® technology was undertaken within the Department of Pharmacy & Pharmacology at the University of Bath, and subsequently by Vectura. This has directly provided the basis for novel, potentially life-saving treatments for chronic obstructive pulmonary disease (COPD). Seebri® Breezhaler® and Ultibro® Breezhaler® are once-daily, maintenance bronchodilators for the relief of various symptoms due to airways obstruction caused by COPD. Seebri® Breezhaler® was approved in the EU and Japan at the end of 2012 and has now been launched by Novartis. Ultibro® Breezhaler® a first-in-class combination bronchodilator was approved in Japan and the EU in September 2013. Under the terms of the licence agreement with Novartis concerning these products, Vectura has already received $52.5M with an additional >$100M anticipated upon achievement of regulatory and commercialisation targets. These medicines are major advances to treat and manage a disease that, according to the WHO, affects an estimated 210 million people worldwide and was the third leading cause of death in the developed world in 2012.

Submitting Institution

University of Bath

Unit of Assessment

Allied Health Professions, Dentistry, Nursing and Pharmacy

Summary Impact Type

Technological

Research Subject Area(s)

Engineering: Chemical Engineering
Medical and Health Sciences: Cardiorespiratory Medicine and Haematology, Pharmacology and Pharmaceutical Sciences

3. Inhaled medicines: Leveraging benefits to global pharma and international development.

Summary of the impact

i2c Pharmaceutical Services is the trading name for a Cardiff University spin-out company based on Cardiff University research excellence and specialising in pharmaceutical inhaler product research and development. i2c's research in formulation technologies and clinical testing has enabled development of new inhalational medicinal products for the healthcare markets in both developed and emerging countries. Impacts arising from research are at local, national and international levels and evidenced by marketed products, the improved business performance of commercial concerns and the creation of highly skilled jobs.

Submitting Institution

Cardiff University

Unit of Assessment

Allied Health Professions, Dentistry, Nursing and Pharmacy

Summary Impact Type

Technological

Research Subject Area(s)

Medical and Health Sciences: Cardiorespiratory Medicine and Haematology, Pharmacology and Pharmaceutical Sciences

Managing risk associated with crystal polymorphism in pharmaceutical development

Summary of the impact

Nearly all solid dosage forms contain drugs in crystalline form; and all crystals have the potential to `morph', suddenly, into different forms which can affect the safety and efficacy of the medicinal product. A number of high-profile cases in which marketed medicines had to be withdrawn [Lee, et al., Annu. Rev. Chem. Biomol. Eng. 2011, 2, 259-280] led multinational drug company Pfizer to conclude that a greater understanding of polymorphism was required to enable drug product design for the 21st Century. The University of Greenwich pioneered methods to predict crystal behaviour on the shelf and during manufacture that were affordable, timely and effective. It enabled Pfizer to select the optimal polymorphic drug form and manage risk associated with uncontrolled solid-state transformations, thereby safeguarding patients and avoiding huge costs.

Submitting Institution

University of Greenwich

Unit of Assessment

Chemistry

Summary Impact Type

Technological

Research Subject Area(s)

Chemical Sciences: Analytical Chemistry, Inorganic Chemistry, Physical Chemistry (incl. Structural)

Development of more effective technologies for oral delivery of drugs via improved understanding of the physiological features of the gastrointestinal tract

Summary of the impact

Research by Professor Abdul Basit's group at the UCL School of Pharmacy is leading to improved treatments for ulcerative colitis and other conditions through increased knowledge of the complex physiology of the gastrointestinal tract. Improved understanding of in vivo drug release and uptake has allowed development of three patent-protected technologies for improved drug delivery: PHLORALTM, for release of drugs in the colon, and DuoCoatTM and ProReleaseTM formulations designed to allow intact transit through the stomach followed by immediate release upon gastric emptying. These technologies are the subject of licences and ongoing development programmes, with PHLORALTM currently in phase III clinical trials. The impact is therefore the introduction of enabling technologies that have positively influenced the drug development programmes of pharmaceutical companies.

Submitting Institution

University College London

Unit of Assessment

Allied Health Professions, Dentistry, Nursing and Pharmacy

Summary Impact Type

Technological

Research Subject Area(s)

Medical and Health Sciences: Clinical Sciences, Neurosciences, Pharmacology and Pharmaceutical Sciences

Supporting regulatory approval of poorly soluble drugs for HIV and Hepatitis C

Summary of the impact

Research by the School of Pharmacy played a key role in the 2008 regulatory approval of Janssen Pharmaceutica's HIV drug Intelence®. As a poorly soluble drug, Intelence® required specialist formulation and was the first formulation of its type to be approved by the FDA and EMA. Intelence® offers significantly improved clinical outcomes due to its efficacy in patients with HIV resistance. Global Intelence® sales in 2012 were $349M, with additional not-for-profit supplies to resource-limited countries. As a result of this landmark regulatory approval formulation development strategies at Janssen were adapted enabling a further poorly soluble drug to reach the market. Telaprevir, a second-generation Hepatitis C treatment (marketed as Incivek®, Incivo® & Telavic®), gained global regulatory approval in 2011. 2012 sales exceeded $1bn in the US alone.

Submitting Institution

University of Nottingham

Unit of Assessment

Allied Health Professions, Dentistry, Nursing and Pharmacy

Summary Impact Type

Technological

Research Subject Area(s)

Chemical Sciences: Analytical Chemistry, Macromolecular and Materials Chemistry, Physical Chemistry (incl. Structural)

Developing improved pre-clinical testing strategies to reduce the drug attrition of inhaled drug compounds at pre-clinical assessment.

Summary of the impact

Edinburgh Napier University is internationally recognised for its research into the mechanisms that drive the adverse health effects of inhaled particles. Pharmaceutical company GlaxoSmithKline (GSK) required early understanding of the likelihood that inhaled drug particulates, used in the treatment of asthma, would evoke an adverse biological response, thus compromising the development of any novel drug. Through collaboration, via a Knowledge Transfer Partnership (KTP), we were able to develop improved in vitro methodologies to study toxicity and, thus, predict pathologies reported in vivo with the aim of reducing both the use of animals and pre-clinical drug attrition.

Submitting Institution

Edinburgh Napier University

Unit of Assessment

Allied Health Professions, Dentistry, Nursing and Pharmacy

Summary Impact Type

Technological

Research Subject Area(s)

Medical and Health Sciences: Cardiorespiratory Medicine and Haematology, Pharmacology and Pharmaceutical Sciences

Improved drug discovery and development through use of novel iridium catalysts

Summary of the impact

Labelled compounds form an essential part of drug discovery and development within the pharmaceutical industry. Novel iridium catalysts, developed by Kerr at WestCHEM since 2008, have introduced a step-change in the ability to label pharmaceutical candidate compounds with radioactive (tritium) or non-radioactive (deuterium) isotopes.

The catalysts are applicable to specific types of compounds that comprise approximately one-third of all drug candidates. Advantages of the catalysts include greater efficacy (less catalyst needed and higher yield of labelled product, giving cost savings), greater speed (efficiency savings), and a significant decrease in radioactive waste compared with previous methods (environmental and safety benefits).

Even since 2008, their adoption within the pharmaceutical industry has been extremely rapid; e.g., the multinational pharmaceutical company AstraZeneca now applies the Kerr methodology to 90% of their relevant candidate compounds. Additional impact has been achieved by Strem Chemicals who have been manufacturing and marketing the catalysts worldwide since October 2012. Even in that very short period, multiple sales have been made on three continents providing economic benefit to the company.

Submitting Institutions

University of Strathclyde,University of Glasgow

Unit of Assessment

Chemistry

Summary Impact Type

Technological

Research Subject Area(s)

Chemical Sciences: Organic Chemistry
Medical and Health Sciences: Pharmacology and Pharmaceutical Sciences

Exploiting Spatial Light Scattering (SLS) for Particle Characterisation

Summary of the impact

Since 1994, the university has pioneered the development of spatial light scattering for the rapid detection and classification of various types of airborne particle. This `particle thumbprint' technology, based on an analysis of the detailed 2-dimensional pattern of light scattered by each particle, has since found worldwide application.

Over the 2008-13 period, the technology was exploited by commercial companies and research organisations from the USA, mainland Europe, the UK and Japan in areas including military bioaerosol detection; atmospheric cloud microphysics and climate research; particle/powder process control; stack emissions monitoring; environmental pollution assessment; and, most recently, the real-time detection of hazardous airborne asbestos fibres.

Submitting Institution

University of Hertfordshire

Unit of Assessment

Physics

Summary Impact Type

Technological

Research Subject Area(s)

Physical Sciences: Other Physical Sciences

Intelligent Fingerprinting Ltd. – a spin out company from the School of Chemistry

Summary of the impact

The spin-out company Intelligent Fingerprinting Ltd. was founded in 2007, based on Professor David Russell's research. The company develops novel technologies using antibody-nanoparticle reagents to detect drugs and drug metabolites in latent fingerprints whilst simultaneously providing high resolution fingerprint images for identification purposes. Combining these technologies with a fluorescence-based hand-held reader provides a non-invasive diagnostic platform for use in the criminal justice sector, institutional testing and hospital environments.

Total funding to date for the company has been >£3.2M in four investment rounds. The company employs 11 staff, who work in dedicated office and laboratory premises within the Norwich Research Park Innovation Centre.

The company received its first purchase order from the UK Home Office in 2012. A distribution agreement is in place with Dallas-based SmarTox Inc. for North American sales of Intelligent Fingerprinting products for `Drugs of Abuse' testing.

Submitting Institution

University of East Anglia

Unit of Assessment

Chemistry

Summary Impact Type

Technological

Research Subject Area(s)

Chemical Sciences: Analytical Chemistry, Organic Chemistry
Medical and Health Sciences: Pharmacology and Pharmaceutical Sciences

Abraham solvation parameter approach benefiting the chemical industries

Summary of the impact

The Abraham solvation parameter approach developed at UCL has become integral to the work carried out by drug discovery teams at [text removed for publication] and other major pharmaceutical companies, as well as research and development groups at international chemical companies including Syngenta and [text removed for publication]. It enables chemists to predict physicochemical and biochemical properties of chemicals, including drugs and agrochemicals, rapidly and efficiently, without the need to conduct time-consuming experiments. The method helps drug discovery teams to identify and optimise the most promising compounds, and often results in fewer compounds being made before a candidate is selected, saving time and resources. The approach has been integrated into software used for drug discovery [text removed for publication].

Submitting Institution

University College London

Unit of Assessment

Chemistry

Summary Impact Type

Technological

Research Subject Area(s)

Chemical Sciences: Physical Chemistry (incl. Structural), Theoretical and Computational Chemistry
Biological Sciences: Biochemistry and Cell Biology

Filter Impact Case Studies

Download Impact Case Studies